Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Puma Biotech (PBYI) Tops Q4 EPS by 15c
February 25, 2021 5:30 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.14), $0.15 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.6 million versus the consensus estimate of $52.79 million.
During the fourth quarter of 2020 Puma continued to be negatively impacted by the challenges of COVID-19; however, we were pleased to be able to achieve NERLYNX revenues that were within the previously stated guidance, said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. Our year concluded with a number of positive clinical milestones for the Company, including the publication of ExteNET data in Clinical... More
